BioCentury
ARTICLE | Company News

Adimab licenses discovery platform to GSK, Biogen Idec

July 27, 2013 12:43 AM UTC

Adimab LLC (Lebanon, N.H.) announced two separate deals on Friday in which the biotech for the first time is allowing companies to internalize its yeast-based antibody discovery platform. Adimab granted Biogen Idec Inc. (NASDAQ:BIIB) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) non-exclusive licenses to use Adimab's platform to discover and optimize antibody-based therapeutics, including bispecific antibodies.

Biogen Idec and GSK will receive a unique, custom human antibody library that is exclusive to each company and an option to receive platform improvements, including access to new antibody libraries. Under both deals, Adimab will receive an undisclosed upfront payment and is eligible for undisclosed milestones, plus royalties. ...